Healthcare Providers' and Pregnant People's Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus

• Published in: Vaccines (Basel) 2024-05, Vol.12 (5), p.560
• Main Authors: Beusterien, Kathleen M, Law, Amy W, Maculaitis, Martine C, Will, Oliver, Kopenhafer, Lewis, Olsen, Patrick, Hauber, Brett, Vietri, Jeffrey T, Cappelleri, Joseph C, Coulter, Joshua R, Shea, Kimberly M
• Format: Article
• Language: English
• Subjects: Approximation; Babies; Children; Disease prevention; Diseases; Effectiveness; Estimates; FDA approval; Gestational age; Health care; Health care industry; healthcare providers; Hospitalization; Illnesses; Infants; Infections; Informed consent; Injection; maternal vaccination; Monoclonal antibodies; Palivizumab; Pediatrics; Pharmaceutical industry; Pregnancy; pregnant people; Pregnant women; Respiratory syncytial virus; Sample size; stakeholder preferences; Vaccines; Viral infections
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines12050560

We assessed the impact of respiratory syncytial virus (RSV) preventive characteristics on the intentions of pregnant people and healthcare providers (HCPs) to protect infants with a maternal vaccine or monoclonal antibodies (mAbs). Pregnant people and HCPs who treated pregnant people and/or infants were recruited via convenience sample from a general research panel to complete a cross-sectional, web-based survey, including a discrete choice experiment (DCE) wherein respondents chose between hypothetical RSV preventive profiles varying on five attributes (effectiveness, preventive type [maternal vaccine vs. mAb], injection recipient/timing, type of medical visit required to receive the injection, and duration of protection during RSV season) and a no-preventive option. A best-worst scaling (BWS) exercise was included to explore the impact of additional attributes on preventive preferences. Data were collected between October and November 2022. Attribute-level preference weights and relative importance (RI) were estimated. Overall, 992 pregnant people and 310 HCPs participated. A preventive (vs. none) was chosen 89.2% (pregnant people) and 96.0% (HCPs) of the time (DCE). Effectiveness was most important to preventive choice for pregnant people (RI = 48.0%) and HCPs (RI = 41.7%); all else equal, pregnant people (RI = 5.5%) and HCPs (RI = 7.2%) preferred the maternal vaccine over mAbs, although preventive type had limited influence on choice. Longer protection, protection starting at birth or the beginning of RSV season, and use for both pre-term and full-term babies were ranked highest in importance (BWS). Pregnant people and HCPs strongly preferred a preventive to protect infants against RSV (vs. none), underscoring the need to incorporate RSV preventives into routine care.